Elevated VEGF concentrations in ascites and serum predict adverse prognosis in ovarian cancer

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 73, Issue 4, 2013, Pages 309-314

  Liang, Bin ^a   Guo, Zhengdong ^a   Li, Yunhui ^b   Liu, Chuan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b No 202 Hospital of PLA   (China)

Author keywords

Biomarker; Lymphangiogenesis; Metastasis; Tumor; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN C; TUMOR MARKER; VEGFC PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ASCITES; BENIGN TUMOR; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GYNECOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARY TUMOR; PATHOLOGY; PROGNOSIS; YOUNG ADULT;

ADULT; AGED; ASCITES; BIOMARKERS, TUMOR; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR C; YOUNG ADULT;

EID: 84879070450     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2013.773593     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Hao Y, X u J, M urray T, T hun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58 :71-96
2. Naora H, M ontell D J. O varian cancer metastasis: Integrating insights from disparate model organisms. Nat Rev Cancer 2005; 5 : 355-66
3. Bast R C Jr, H ennessy B, M ills G B. The biology of ovarian cancer: New opportunities for translation. Nat Rev Cancer 2009; 9 : 415-28
4. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351 : 2519-29
5. Bristow RE, T omacruz RS, A rmstrong DK, T rimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-Analysis. J Clin Oncol 2002; 20 : 1248-59
6. Holschneider C H, B erek J S. O varian cancer: Epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000; 19 : 3-10
7. Huang KJ, S ui LH. The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer. Med Oncol 2012; 29 : 318-23
8. Zhao RW, Y ang SH, C ai LQ, Z hang J, W ang J, W ang ZH. [Roles of vascular endothelial growth factor and plateletderived growth factor in lymphangiogenesis in epithelial ovarian carcinoma.]. Zhonghua Fu Chan Ke Za Zhi 2009; 44 : 760-4
9. Sinn BV, D arb-Esfahani S, W irtz RM, F aggad A, W eichert W, Buckendahl AC, Noske A, Muller BM, Budczies J, Sehouli J, Braicu EI, Dietel M, Denkert C. Vascular endothelial growth factor C mRNA expression is a prognostic factor in epithelial ovarian cancer as detected by kinetic RT-PCR in formalin-fi xed paraffi n-embedded tissue. Virchows Arch 2009; 455 : 461-7
10. Ueda M, H ung YC, T erai Y, K anda K, K anemura M, Futakuchi H, Yamaguchi H, Akise D, Yasuda M, Ueki M. Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas. Clin Cancer Res 2005; 11 : 3225-32
11. Joukov V, P ajusola K, K aipainen A, C hilov D, L ahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996; 15 : 290-8
12. Plate K. From angiogenesis to lymphangiogenesis. N at Med 2001 ; 7 : 151-2
13. Han FH, L i HM, Z heng DH, H e YL, Z han WH. The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol 2010; 36 : 1172-9
14. Gu Y, Q i X, G uo S. L ymphangiogenesis induced by VEGF-C and VEGF-D promotes metastasis and a poor outcome in breast carcinoma: A retrospective study of 61 cases. Clin Exp Metastasis 2008; 25 : 717-25
15. Garcia E A, S imoes K, W akamatsu A, R essio R A, A lves V A, Longatto-Filho A, Camargo RS. Lymphatic vessel density and VEGF-C expression are signifi cantly different among benign and malignant thyroid lesions. Endocr Pathol 2010; 21 : 101-7
16. Ma D M, X u Y P, Z hu L. Expression of vascular endothelial growth factor C correlates with a poor prognosis based on analysis of prognostic factors in patients with cervical carcinomas. J Obstet Gynaecol Res 2011; 37 : 1519-24
17. Nishida N, Y ano H, K omai K, N ishida T, K amura T, K ojiro M. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 2004; 101 : 1364-74
18. Woopen H, S ehouli J. C urrent and future options in the treatment of malignant ascites in ovarian cancer. Anticancer Res 2009; 29 : 3353-9
19. Geisler JP, M iller GA, L ee TH, H arwood RM, W iemann MC, Geisler HE. Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma. J Reprod Med 1996; 41 : 140-2
20. Gadducci A, F erdeghini M, C osio S, F anucchi A, C ristofani R, Genazzani AR. The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer. Int J Gynecol Cancer 2001; 11 : 277-82
21. Diamandis EP, S corilas A, F racchioli S, V an Gramberen M, De Bruijn H, Henrik A, Soosaipillai A, Grass L, Yousef GM, Stenman UH, Massobrio M, Van Der Zee AG, Vergote I, Katsaros D. Human kallikrein 6 (hK6): A new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 2003; 21 : 1035-43
22. Luo LY, K atsaros D, S corilas A, F racchioli S, B ellino R, van Gramberen M, de Bruijn H, Henrik A, Stenman UH, Massobrio M, Van Der Zee AG, Vergote I, Diamandis EP. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 2003; 63 : 807-11
23. Lane D, M atte I, R ancourt C, P iche A. P rognostic signifi-cance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer 2011; 11 : 210
24. Marth C, F iegl H, Z eimet AG, M uller-Holzner E, D eibl M, Doppler W, Daxenbichler G. Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol 2004; 191 : 1598-605
25. Hefler L, M ayerhofer K, N ardi A, R einthaller A, K ainz C, Tempfer C. Serum soluble Fas levels in ovarian cancer. Obstet Gynecol 2000; 96 : 65-9
26. Hefler LA, Z eillinger R, G rimm C, S ood A K, C heng WF, Gadducci A, Tempfer CB, Reinthaller A. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol 2006; 103 : 512-7
27. Koh S C, K halil R, L im F K, I lancheran A, C hoolani M. The association between fi brinogen, von Willebrand Factor, antithrombin III, and D-dimer levels and survival outcome by 36 months from ovarian cancer. Clin Appl Thromb Hemost 2006; 12 : 3-8
28. Modugno F. Ovarian cancer and high-risk women-i mplications for prevention, screening, and early detection. Gynecol Oncol 2003; 91 : 15-31
29. Alitalo A, D etmar M. I nteraction of tumor cells and lymphatic vessels in cancer progression. Oncogene 2011; 31 : 4499-508
30. The XW, Y u X, L iu T, Y u SY, C hen DJ. V ector-based RNA interference against vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of colorectal cancer in vivo in mice. Chin Med J (Engl) 2008; 121 : 439-44
31. Sangoi A R, M cKenney JK, D adras SS, L ongacre T A. L ymphatic vascular invasion in ovarian serous tumors of low malignant potential with stromal microinvasion: A case control study. Am J Surg Pathol 2008; 32 : 261-8
32. Jeon B H, J ang C, H an J, K ataru R P, P iao L, J ung K, C ha HJ, Schwendener RA, Jang KY, Kim KS, Alitalo K, Koh GY. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b - macrophages in advanced ovarian cancer. Cancer Res 2008; 68 : 1100-9
33. Skobe M, H awighorst T, J ackson D G, P revo R, J anes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7 : 192-8
34. Stacker SA, Baldwin ME, A chen MG. The role of tumor lymphangiogenesis in metastatic spread. FASEB J 2002; 16 : 922-34
35. Beasley N J, P revo R, B anerji S, L eek R D, M oore J, v an Trappen P, Cox G, Harris AL, Jackson DG. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 2002; 62 : 1315-20
36. Dadras S S, P aul T, B ertoncini J, B rown L F, M uzikansky A, Jackson DG, Ellwanger U, Garbe C, Mihm MC, Detmar M. Tumor lymphangiogenesis: A novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003; 162 : 1951-60
37. Ohno F, N akanishi H, A be A, S eki Y, K inoshita A, Hasegawa Y, Tatematsu M, Kurita K. Regional difference in intratumoral lymphangiogenesis of oral squamous cell carcinomas evaluated by immunohistochemistry using D2-40 and podoplanin antibody: An analysis in comparison with angiogenesis. J Oral Pathol Med 2007; 36 : 281-9
38. Mello M F, C osta A F, F reitas L L, S oares AB, A raujo V C, Tincani AJ, Martins AS, Altemani A. Lymphatic vessel density and expressions of lymphangiogenic growth factors in salivary carcinomas. Neoplasma 2011; 58 : 331-6
39. M öb ius C, F reire J, B ecker I, F eith M, B rucher BL, H ennig M, Siewert JR, Stein HJ. VEGF-C expression in squamous cell carcinoma and adenocarcinoma of the esophagus. World J Surg 2007 ; 31 : 1768-72; discussion 73-4
40. Gou HF, C hen XC, Z hu J, J iang M, Y ang Y, C ao D, H ou M. Expressions of COX-2 and VEGF-C in gastric cancer: Correlations with lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res 2011; 30 : 14
41. Van Der Auwera I, C ao Y, Tille J C, P epper M S, J ackson D G, Fox SB, Harris AL, Dirix LY, Vermeulen PB. First international consensus on the methodology of lymphangiogenesis quantifi cation in solid human tumours. Br J Cancer 2006; 95 : 1611-25